Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 2,250 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 2,250 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the transaction, the insider now directly owns 14,967 shares in the company, valued at $1,496,700. This trade represents a 13.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ariel Hurley also recently made the following trade(s):

• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94.

Blueprint Medicines Stock Up 2.3 %

NASDAQ BPMC opened at $104.89 on Thursday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The company has a market cap of $6.66 billion, a price-to-earnings ratio of -49.71 and a beta of 0.61. The company has a 50 day moving average of $93.75 and a 200-day moving average of $95.29. Blueprint Medicines Co. has a 1-year low of $72.24 and a 1-year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the company posted ($2.20) EPS. The company’s revenue was up 126.5% compared to the same quarter last year. On average, equities research analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

A number of large investors have recently bought and sold shares of the company. Quarry LP bought a new stake in shares of Blueprint Medicines during the 3rd quarter worth approximately $32,000. Covestor Ltd lifted its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $108,000. Values First Advisors Inc. bought a new position in shares of Blueprint Medicines in the 3rd quarter valued at $122,000. Finally, CWM LLC raised its holdings in shares of Blueprint Medicines by 69.2% during the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock worth $173,000 after buying an additional 765 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BPMC. UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective on the stock. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research report on Wednesday. Wells Fargo & Company decreased their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. began coverage on Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.72.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.